Specificity of the autologous neutralizing antibody response
- PMID: 20048698
- PMCID: PMC3004050
- DOI: 10.1097/COH.0b013e32832ea7e8
Specificity of the autologous neutralizing antibody response
Abstract
Purpose of review: It has long been known that autologous neutralizing antibodies (AnAbs) exert pressure on the envelope of HIV, resulting in neutralization escape. However, recently, progress has been made in uncovering the precise targets of these potent early antibodies.
Recent findings: AnAbs primarily target variable regions of the HIV-1 envelope, explaining the strain-specificity of these antibodies. Despite high neutralizing potential and cross-reactivity, anti-V3 antibodies do not contribute to autologous neutralization. The V1V2 is commonly immunogenic in early HIV-1 and simian human immunodeficiency virus infections, though the nature of these epitopes remains to be determined. In subtype C viruses, the C3 region is a neutralization target, possibly as a result of its more exposed and amphipathic structure. Autologous neutralization appears to be mediated by very few AnAb specificities that develop sequentially suggesting the possibility of immunological hierarchies for both binding and neutralizing antibodies. The role of AnAbs in preventing superinfection and in restricting virus replication is reexamined in the context of recent data.
Summary: New studies have greatly contributed toward our understanding of the specificities mediating autologous neutralization and highlighted potential vulnerabilities on transmitted viruses. However, the contribution of AnAbs to the development of neutralization breadth remains to be characterized.
Similar articles
-
Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15. J Virol. 2016. PMID: 26763999 Free PMC article.
-
Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.J Virol. 2023 Feb 28;97(2):e0163522. doi: 10.1128/jvi.01635-22. Epub 2023 Feb 7. J Virol. 2023. PMID: 36749076 Free PMC article.
-
HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.J Virol. 2017 Oct 13;91(21):e00910-17. doi: 10.1128/JVI.00910-17. Print 2017 Nov 1. J Virol. 2017. PMID: 28835491 Free PMC article.
-
Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.Retrovirology. 2016 Jun 15;13(1):41. doi: 10.1186/s12977-016-0273-x. Retrovirology. 2016. PMID: 27307004 Free PMC article.
-
The Neutralizing Antibody Response to the HIV-1 Env Protein.Curr HIV Res. 2018;16(1):21-28. doi: 10.2174/1570162X15666171124122044. Curr HIV Res. 2018. PMID: 29173180 Free PMC article. Review.
Cited by
-
Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption.Sci Transl Med. 2023 May 10;15(695):eabq4490. doi: 10.1126/scitranslmed.abq4490. Epub 2023 May 10. Sci Transl Med. 2023. PMID: 37163616 Free PMC article.
-
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape.PLoS Pathog. 2012;8(5):e1002721. doi: 10.1371/journal.ppat.1002721. Epub 2012 May 31. PLoS Pathog. 2012. PMID: 22693447 Free PMC article.
-
Spatiotemporal hierarchy in antibody recognition against transmitted HIV-1 envelope glycoprotein during natural infection.Retrovirology. 2016 Feb 17;13:12. doi: 10.1186/s12977-016-0243-3. Retrovirology. 2016. PMID: 26883323 Free PMC article.
-
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.J Virol. 2012 Jan;86(2):930-46. doi: 10.1128/JVI.06126-11. Epub 2011 Nov 9. J Virol. 2012. PMID: 22072758 Free PMC article.
-
Induction of immunity to human immunodeficiency virus type-1 by vaccination.Immunity. 2010 Oct 29;33(4):542-54. doi: 10.1016/j.immuni.2010.09.011. Immunity. 2010. PMID: 21029964 Free PMC article. Review.
References
-
- Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307–312. - PubMed
-
-
Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008;82:12449–12463. First detailed analysis of the ontogeny of B cell responses to transmitted HIV-1 subtype B viruses, showing a relatively well-defined hierarchy of binding antibody responses starting from 8 days after the detection of viremia which precede the development of neutralizing antibody responses.
-
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous